| Jean Fletcher, | |
|
6785 Berwick Tpke, Columbia Cross Roads, PA 16914-8269 | |
| (570) 596-3943 | |
| Not Available |
| Full Name | Jean Fletcher |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 6785 Berwick Tpke, Columbia Cross Roads, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851801807 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 326564-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jean Fletcher, 6785 Berwick Tpke, Columbia Crossroads, PA 16914 Ph: () - | Jean Fletcher, 6785 Berwick Tpke, Columbia Cross Roads, PA 16914-8269 Ph: (570) 596-3943 |
News Archive
Duke Medicine researchers studying the interaction of blood stem cells and the niche where they reside have identified a protein that may be a long-sought growth factor for blood stem cells.
Among patients with suspected or known coronary artery disease, use of a method that applies computational fluid dynamics to derive certain data from computed tomographic (CT) angiography demonstrated improved diagnostic accuracy vs. CT angiography alone for the diagnosis of ischemia, according to a study being published online by JAMA.
NHS partnership Health Call is rolling out a new digital outpatients service to connect clinicians with patients at home and minimize the need to attend hospital appointments in person during the pandemic.
The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy.
A team of researchers in France have observed that the "standard" 2 dose regimen for mRNA COVID-19 vaccines could provide adequate protection to only a few KTRs. It has also been shown in multiple studies that a considerable population of vaccinated KTRs were easily infected with SARS-CoV-2.
› Verified 8 days ago